You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

42 search results for: disease control

ADVENT On Air | Early Intervention and <b>Disease</b> Modification in Atopic Dermatitis

Podcast

ADVENT On Air | Early Intervention and Disease Modification in Atopic Dermatitis

20 min

Dermatology

Prof. Thomas Bieber explores early intervention and disease modification in atopic dermatitis.

interactivity

Pediatric Asthma Patient Case Tool: Ash

5 min

Pulmonology

Review a patient case to learn more about identifying uncontrolled asthma and type 2 inflammation in pediatric patients

Emerging Perspectives on the <b>Disease</b> Burden and Management of Children With Atopic Dermatitis

expert video

Emerging Perspectives on the Disease Burden and Management of Children With Atopic Dermatitis

57 min

Dermatology

This video of the October 2024 ADVENT symposium at EAPS in Vienna, Austria features Drs Christine Bangert, Mark Boguniewicz, and Perla Lansang as they discuss the inflammatory processes driven by type 2 cytokines that lead to AD and atopic comorbidities, the multidimensional and cumulative disease burden associated with AD and its comorbidities, and the current and emerging treatment options for children with AD uncontrolled with topical therapy

expert video

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

7 min

Rhinology

Prof. Joaquim Mullol describes the burdens of smell loss and nasal congestion for patients with uncontrolled and/or severe CRSwNP.

Targeting Underlying Inflammation in CRSwNP, a Type 2 Inflammatory <b>Disease</b>

expert video

Targeting Underlying Inflammation in CRSwNP, a Type 2 Inflammatory Disease

10 min

Rhinology

Professor Martin Wagenmann describes the mechanisms through which type 2 inflammation drives symptoms in patients with CRSwNP.

interactivity

Type 2 Inflammation Digital Assessment Tool

4 min

Pulmonology

Learn how to assess patients for the presence of uncontrolled asthma driven by underlying type 2 inflammation.

expert video

Biologics in CRSwNP: Comparative Efficacy and Real-World Effectiveness

10 min

Rhinology

Professor Eugenio De Corso discusses indirect comparisons of biologics approved for patients with uncontrolled CRSwNP and emerging real-world effectiveness of biologics for patients with CRSwNP.

Why targeting Type 2 Inflammation is important in the treatment of skin <b>disease</b>s like AD, PN and CSU

expert video

Why targeting Type 2 Inflammation is important in the treatment of skin diseases like AD, PN and CSU

5 min

Dermatology

Dr. Palomares discusses how type 2 inflammation, an aberrant immune response, underlies skin diseases like atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria, linking to their clinical symptoms.

CRSwNP: A Chronic Type 2 Inflammatory <b>Disease</b>

expert video

CRSwNP: A Chronic Type 2 Inflammatory Disease

2 min

Rhinology

Prof. Peter Hellings describes how type 2 inflammation drives CRSwNP.

expert video

Can Early Intervention Shape the Course of Atopic Dermatitis?

15 min

Dermatology

Exploring the concept of disease modification through early intervention with targeted systemic therapies in atopic dermatitis.

interactivity

Adult Asthma Interactive Patient Cases

15 min

Pulmonology

Explore 3 hypothetical patient cases using guideline-based checklists for assessment and diagnosis of type 2 inflammation in adult asthma

expert video

IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in CRSwNP

30 min

Rhinology

Prof. Joaquim Mullol presents on the proposed mechanisms of smell loss and nasal congestion in CRSwNP.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Czech RepublicChange country/region